Hemodynamic effects of 1-hydrazinophthalazine in the dog, with special reference to circulating splanchnic blood volume. 1955

P A MARKS, and P C REYNELL, and S E BRADLEY

UI MeSH Term Description Entries
D001810 Blood Volume Volume of circulating BLOOD. It is the sum of the PLASMA VOLUME and ERYTHROCYTE VOLUME. Blood Volumes,Volume, Blood,Volumes, Blood
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006830 Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Hydrallazin,Apresoline,Apressin,Apressoline,Hydralazine Hydrochloride,Hydralazine mono-Hydrochloride,Hydrazinophthalazine,Nepresol,Hydralazine mono Hydrochloride,Hydrochloride, Hydralazine,mono-Hydrochloride, Hydralazine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013152 Splanchnic Circulation The circulation of blood through the BLOOD VESSELS supplying the abdominal VISCERA. Mesenteric Circulation,Circulation, Mesenteric,Circulation, Splanchnic,Circulations, Mesenteric,Circulations, Splanchnic,Mesenteric Circulations,Splanchnic Circulations
D013565 Sympatholytics Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. Sympathetic-Blocking Agents,Sympatholytic,Sympatholytic Agent,Sympatholytic Drug,Sympatholytic Agents,Sympatholytic Drugs,Sympatholytic Effect,Sympatholytic Effects,Agent, Sympatholytic,Agents, Sympathetic-Blocking,Agents, Sympatholytic,Drug, Sympatholytic,Drugs, Sympatholytic,Effect, Sympatholytic,Effects, Sympatholytic,Sympathetic Blocking Agents

Related Publications

P A MARKS, and P C REYNELL, and S E BRADLEY
June 1957, The Journal of clinical investigation,
P A MARKS, and P C REYNELL, and S E BRADLEY
January 1963, Circulation research,
P A MARKS, and P C REYNELL, and S E BRADLEY
January 1955, The Journal of clinical investigation,
P A MARKS, and P C REYNELL, and S E BRADLEY
August 1953, Circulation,
P A MARKS, and P C REYNELL, and S E BRADLEY
May 1966, Circulation research,
P A MARKS, and P C REYNELL, and S E BRADLEY
November 1955, The Journal of the Kansas Medical Society,
Copied contents to your clipboard!